Rani Therapeutics (RANI) Competitors

Rani Therapeutics (NASDAQ:RANI) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment.

Do analysts recommend RANI or BNTC?

Rani Therapeutics presently has a consensus target price of $12.33, suggesting a potential upside of 806.86%. Benitec Biopharma has a consensus target price of $24.43, suggesting a potential upside of 81.90%. Given Rani Therapeutics' higher probable upside, research analysts clearly believe Rani Therapeutics is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Benitec Biopharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22

Which has more volatility and risk, RANI or BNTC?

Rani Therapeutics has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Does the media prefer RANI or BNTC?

In the previous week, Benitec Biopharma had 7 more articles in the media than Rani Therapeutics. MarketBeat recorded 14 mentions for Benitec Biopharma and 7 mentions for Rani Therapeutics. Benitec Biopharma's average media sentiment score of 0.78 beat Rani Therapeutics' score of 0.51 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Benitec Biopharma	3 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, RANI or BNTC?

Benitec Biopharma has higher revenue and earnings than Rani Therapeutics. Benitec Biopharma is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	N/A	N/A	-$33.97M	-$1.06	-1.28
Benitec Biopharma	$80K	3,936.84	-$21.75M	-$1.51	-8.89

Do insiders and institutionals have more ownership in RANI or BNTC?

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 53.3% of Rani Therapeutics shares are owned by insiders. Comparatively, 1.3% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is RANI or BNTC more profitable?

Benitec Biopharma's return on equity of -44.61% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-219.64%	-56.71%
Benitec Biopharma	N/A	-44.61%	-41.25%

Does the MarketBeat Community favor RANI or BNTC?

Benitec Biopharma received 163 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 82.50% of users gave Rani Therapeutics an outperform vote while only 65.55% of users gave Benitec Biopharma an outperform vote.

Company	Underperform	Outperform
Rani Therapeutics	Outperform Votes 33 82.50%	Underperform Votes 7 17.50%
Benitec Biopharma	Outperform Votes 196 65.55%	Underperform Votes 103 34.45%

Summary

Benitec Biopharma beats Rani Therapeutics on 12 of the 17 factors compared between the two stocks.